Pharmacy “Fee-For-Service” Model Could Aid Chronic-Use OTC Switches
This article was originally published in The Tan Sheet
Executive Summary
A pharmacy "fee-for-service" model could create a "de facto third class" of drugs that would facilitate over-the-counter switches for chronic-use medications, SDM, Inc. President Bill Howard, PhD, suggested at an IIR conference on Rx-to-OTC switches in Philadelphia Nov. 20
You may also be interested in...
OTC Drug Spending By Some Insurers Hindered By Antitrust Law
Statutory caps on nonprescription drug spending by not-for-profit insurers could pose a significant barrier to expanded use of over-the-counter products
Merck Remains Active In Pursuit Of Mevacor Rx-to-OTC Switch In U.S.
Merck continues to work with FDA over a possible switch of Mevacor (lovastatin) to over-the-counter status in the U.S. this year
Third Class Of Drugs Back In The News With Proposed UK Statin Switch
J&J/Merck's application to make Zocor available in the UK without a prescription may revive debate in the U.S. regarding creation of a third class of drugs